Clinical and histologic characteristics of 100 patients with transformed MF
| Characteristic . | Value . |
|---|---|
| Male:female | 64:36 |
| Median duration skin lesions before diagnosis MF, mo (range) | 33 (1-480) |
| Median interval between diagnosis MF and LCT, mo (range) | 10 (0-222) |
| Median age at diagnosis MF, y (range) | 64 (29-90) |
| Median age at diagnosis MF with LCT, y (range) | 68 (33-90) |
| Site of LCT | |
| Only skin | 75 |
| Only lymph nodes | 6 |
| Skin + lymph nodes | 19 |
| Stage at MF with LCT | |
| IB | 10 |
| IIB | 65 |
| IV | 25 |
| Folliculotropic MF | |
| Absent | 69 |
| Present | 31 |
| Percent of blast cells | |
| < 25% (clusters, %) | 9 (10) |
| 25%-75% | 39 (41) |
| > 75% | 46 (49) |
| CD30 expression* | |
| 0%-25% | 53 |
| 26%-50% | 0 |
| 51%-75% | 8 |
| 76%-100% | 39 |
| First therapy after LCT | |
| Local radiotherapy† | 44 |
| Total skin electron beam therapy | 12 |
| Polychemotherapy | 28 |
| Other (eg, local steroids, excision, photochemotherapy) | 16 |
| Median duration follow-up after | |
| Start skin lesions, mo (range) | 100 (15-640) |
| Diagnosis MF, mo (range) | 54 (5-318) |
| Transformation, mo (range) | 24 (1-235) |
| Current status | |
| Alive without disease | 6 |
| Alive with disease | 25 |
| Died of lymphoma | 55 |
| Died of other cause | 14 |
| Survival | |
| 2-y DSS/OS, % | 62/57 |
| 5-y DSS/OS, % | 38/33 |
| 10-y DSS/OS, % | 36/24 |
| Characteristic . | Value . |
|---|---|
| Male:female | 64:36 |
| Median duration skin lesions before diagnosis MF, mo (range) | 33 (1-480) |
| Median interval between diagnosis MF and LCT, mo (range) | 10 (0-222) |
| Median age at diagnosis MF, y (range) | 64 (29-90) |
| Median age at diagnosis MF with LCT, y (range) | 68 (33-90) |
| Site of LCT | |
| Only skin | 75 |
| Only lymph nodes | 6 |
| Skin + lymph nodes | 19 |
| Stage at MF with LCT | |
| IB | 10 |
| IIB | 65 |
| IV | 25 |
| Folliculotropic MF | |
| Absent | 69 |
| Present | 31 |
| Percent of blast cells | |
| < 25% (clusters, %) | 9 (10) |
| 25%-75% | 39 (41) |
| > 75% | 46 (49) |
| CD30 expression* | |
| 0%-25% | 53 |
| 26%-50% | 0 |
| 51%-75% | 8 |
| 76%-100% | 39 |
| First therapy after LCT | |
| Local radiotherapy† | 44 |
| Total skin electron beam therapy | 12 |
| Polychemotherapy | 28 |
| Other (eg, local steroids, excision, photochemotherapy) | 16 |
| Median duration follow-up after | |
| Start skin lesions, mo (range) | 100 (15-640) |
| Diagnosis MF, mo (range) | 54 (5-318) |
| Transformation, mo (range) | 24 (1-235) |
| Current status | |
| Alive without disease | 6 |
| Alive with disease | 25 |
| Died of lymphoma | 55 |
| Died of other cause | 14 |
| Survival | |
| 2-y DSS/OS, % | 62/57 |
| 5-y DSS/OS, % | 38/33 |
| 10-y DSS/OS, % | 36/24 |